Researchers at Johns Hopkins have developed an AI-powered blood test that can detect early liver fibrosis and cirrhosis by analyzing how DNA fragments are distributed across the genome, potentially catching disease years before traditional tests would. The breakthrough, published in Science Translational Medicine, represents the first time this fragmentome technology has been systematically applied to chronic noncancer diseases, opening a new frontier in preventive medicine .

Why Current Liver Disease Detection Falls Short?

An estimated 100 million people in the United States have liver conditions that put them at high risk for cirrhosis and cancer, yet most don't know they have the disease. The problem is simple: existing blood tests don't work well enough. Current blood-based markers for fibrosis have limited sensitivity, particularly in early disease, and existing imaging tools like ultrasound or magnetic resonance equipment aren't accessible to everyone .

The stakes are high. Liver fibrosis is reversible in its early stages, but if left undetected, it progresses to cirrhosis and ultimately increases the risk of liver cancer. Current blood testing fails to detect early fibrosis entirely and detects cirrhosis only about half the time, leaving millions of people at risk without knowing it .

How Does This New AI Blood Test Actually Work?

Instead of looking for specific genetic mutations like traditional liquid biopsies, the Johns Hopkins team analyzed something entirely different: the fragmentome. This is the pattern of how DNA pieces are cut, packaged, and distributed across the entire genome. The researchers used whole-genome sequencing to examine cell-free DNA (cfDNA) from 1,576 people with liver disease and other health conditions, analyzing roughly 40 million DNA fragments spanning thousands of genomic regions .

Machine-learning algorithms sorted through these massive datasets to identify disease-specific fragmentation signatures. The scale of data analyzed was enormous compared to other liquid biopsy tests, and the AI technology allowed researchers to zero in on the most informative patterns and develop a classification system that detected early liver disease, advanced fibrosis, and cirrhosis with high sensitivity .

"This builds directly on our earlier fragmentome work in cancer, but now using AI and genome-wide fragmentation profiles of cell-free DNA to focus on chronic diseases. For many of these illnesses, early detection could make a profound difference, and liver fibrosis and cirrhosis are important examples," said Victor Velculescu, co-director of the cancer genetics and epigenetics program at the Johns Hopkins Kimmel Cancer Center.

Victor Velculescu, Co-Director of Cancer Genetics and Epigenetics Program at Johns Hopkins Kimmel Cancer Center

What Makes This Approach Different From Other Blood Tests?

• Fragmentome Analysis: Rather than searching for individual mutations, the test analyzes the entire fragmentome, which contains tremendous information about a person's physiologic state and health conditions.
• Disease-Specific Classifiers: The fragmentome can serve as a foundation for building different classifiers for different diseases, and importantly, these classifiers are disease-specific and do not cross-react with one another.
• Broader Applicability: Beyond liver disease, the study detected fragmentomic signals associated with cardiovascular, inflammatory, and neurodegenerative conditions, suggesting the platform could eventually screen for multiple chronic diseases from a single blood sample.

The research team, co-led by Robert Scharpf, professor of oncology, and Jill Phallen, assistant professor of oncology, emphasized that the power of this approach lies in its scope. Akshaya Annapragada, a biomedical engineering M.D./Ph.D. student working in the Velculescu lab, explained the significance of analyzing the entire fragmentome rather than hunting for specific mutations .

"The fact that we are not looking for individual mutations is what makes this study so powerful. We are analyzing the entire fragmentome, which contains a tremendous amount of information about a person's physiologic state. The scale of these data, coupled with machine learning, enables development of specific classifiers for many different health conditions," noted Akshaya Annapragada.

Akshaya Annapragada, Biomedical Engineering M.D./Ph.D. Student, Johns Hopkins Kimmel Cancer Center

What Did the Study Actually Find?

In a cohort of 570 individuals presenting with suspected serious illness, the team developed a fragmentation comorbidity index that distinguished individuals with high versus low Charlson Comorbidity Index scores, a common tool used by doctors and researchers to estimate how other health conditions may affect a person's risk for death. The fragmentome index independently predicted overall survival and, in some analyses, proved more specific than traditional inflammatory markers .

The researchers also found that some specific fragmentation signatures correlated with worse clinical outcomes. This suggests the test could eventually help doctors not just detect disease, but predict which patients are at highest risk of serious complications .

How to Prepare for This Technology's Clinical Future?

• Stay Informed About Screening Options: If you have risk factors for liver disease, such as hepatitis, heavy alcohol use, or obesity, discuss with your doctor whether you should be screened more frequently as new tests become available.
• Understand Early Intervention Benefits: Early detection of liver fibrosis is crucial because the condition is reversible in its early stages, meaning lifestyle changes or medical interventions could prevent progression to cirrhosis.
• Monitor Emerging Clinical Trials: The Johns Hopkins team is continuing to develop and validate the liver disease classifier, so watch for clinical trial announcements if you're interested in early access to this technology.

What's Next for This Technology?

The researchers emphasize that the liver fibrosis assay described in the study is currently a prototype and not yet a clinical test. Next steps include further development and validation of the liver disease classifier as well as exploration of fragmentome signatures in additional chronic conditions. The study did not include sufficient numbers to develop disease-specific classifiers for cardiovascular, inflammatory, and neurodegenerative conditions, but the researchers suggest broader applicability, which will be one focus of ongoing research .

The potential impact is substantial. If doctors can intervene earlier, before fibrosis progresses to cirrhosis or cancer, the clinical benefit could be enormous. In some cases, early detection of these precursor conditions could have an even greater impact, alerting doctors to treatable conditions that, through intervention, could prevent the development of cancer entirely .

This research, supported in part by the National Institutes of Health, represents a significant shift in how AI is being applied to medicine. Rather than just recognizing patterns in existing data, AI is now helping researchers understand the fundamental biology of disease progression, opening doors to earlier detection and better outcomes for millions of people at risk.